Parvus Therapeutics Inc.-preview

Parvustx

Parvus Therapeutics Inc.

Private

South San Francisco, CaliforniaHealthcare & Life Scienceshttps://parvustx.com/

Last Round

Corporate Funding

Mar 20, 2024

Total Funding Raised

$19.7M

Momentum Score

25 /100

Company Overview

Parvus Therapeutics Inc. is a clinical-stage biotechnology company developing proprietary pMHC nanomedicine drug candidates designed to trigger the in vivo generation of antigen-specific regulatory T cells (Tregs) to treat autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

nanomedicine platformautoimmune disease treatmentNavacimsimmune toleranceTreg inductionregulatory T cellsTregsantigen-specific immunotherapyclinical-stage biotechTreg therapybiotech licensingtolerogenic therapypMHC nanomedicinesin vivo therapyinflammatory bowel diseaseIBD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Parvus Therapeutics Inc. Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Parvus Therapeutics Inc. Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Corporate Funding	Mar 20, 2024
Corporate Funding	Apr 19, 2017
Grant	Jul 30, 2009

View all Funding Rounds

Key People

Founding team and executive leadership

Peter Strumph

Chief Executive Officer

Executive Team

Parvus Therapeutics Inc. Investors

Notable investors and investment history

Investor	Rounds
National Research Council Canada Industrial Research Assistance Program	Grant
Innovate Calgary	Angel

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 19, 2026
Monthly visitors increased 148% MoM, reaching 1.4K.
Jul 15, 2025
Grew 17% QoQ, from 24 to 28 employees.

View all signals

Parvus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Parvus Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Parvus Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California

Employee Range26

Year Founded2009

Last FundingMar 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.